Ultromics, a spinoff of the University of Oxford in the U.K. in collaboration with Mayo Clinic, has raised $55 million in series C funding to expand its heart failure detection platform, EchoGo, to U.S. hospitals.
EchoGo uses artificial intelligence to analyze routine heart ultrasound images and detect two difficult-to-diagnose conditions: HFpEF (heart failure with preserved ejection fraction) and cardiac amyloidosis. The tool is FDA cleared, Medicare reimbursed and requires no new equipment, according to a July 31 HIT Consultant report.
In studies, EchoGo improved HFpEF detection by 73.6% compared to traditional methods. Investors include London-based L&G and Lightrock; Palo Alto, Calif.-based Allegis Capital; Mountain View, Calif.-based Google Ventures; and University of Chicago Medicine.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
